Accuracy of interferon gamma release assays for the COVID-19 immunity assessment

Stieber, Francis; Allen, Nadia; Howard, Jenny; Alagna, Riccardo; Manissero, Davide; Nikolayevskyy, Vladyslav

doi:10.1016/j.jviromet.2022.114472

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Values were subtracted from the Nil value. Cut-off for a positive response was set at 0.15 IU/mL according to the performance of the kit evaluated in cohorts of vaccinated subjects (Krüttgen et al, 2021;Martínez-Gallo et al, 2021;Stieber et al, 2022;Tychala et al, 2021).…”

Section: Quantiferon Sars-cov-2 Ruo Tubesmentioning

confidence: 99%

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

Aiello¹,

Coppola²,

Vanini³

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Section: Quantiferon Sars-cov-2 Ruo Tubesmentioning

confidence: 99%

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

Aiello¹,

Coppola²,

Vanini³

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…With these global demands, various kits of IGRA-format tests and nAb assays have been introduced in the market for the evaluation of humoral and T-cell-mediated responses 5 , 13 , 14 . Although many studies were conducted to confirm the usefulness of these test results 5 – 7 , 9 , 15 , 16 , there is still insufficient evidence that these test results are clinically useful 13 . Therefore, we aimed to determine the changes in these test results before and after COVID-19 booster vaccination, and with respect to the type of COVID-19 vaccination, to confirm whether these test results can be used to predict the risk of SARS-CoV-2 infection over a long-term follow-up period.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, in vitro methods to evaluate the immune status against pathogens consist of two pivotal axes: the neutralizing antibody (nAb) test for the evaluation of B-cell-mediated humoral response and the interferon-γ (INF-γ) release assay (IGRA) against the SARS-CoV-2 antigen for detecting the T-cell mediated response. The clinical performance of these assays has been globally evaluated, and the IGRA format assay is useful for predicting the severity of infection and clinical prognosis for COVID-19 patients and evaluating T-cell immune response following COVID-19 vaccination [5][6][7][8] . Similarly, the nAb test showed acceptable performance for the evaluation of B-cell immune status against COVID-19 in clinical settings 9,10 .…”

mentioning

confidence: 99%

Exploring the vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 in healthcare workers

Lim

Kweon

Choi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

We aimed to analyze the kinetics of T-cell-mediated and B-cell-mediated humoral immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before and after booster vaccination, as well as the impacts of the in vitro test results the type of vaccination on the prediction of SARS-CoV-2 infection. A total of 240 healthcare workers vaccinated twice were serially tested using an interferon gamma release assay (IGRA) and a neutralizing antibody (nAb). At the end of the study, we investigated the history of SARS-CoV-2 infection of all the enrolled participants to analyze the effects of the test results and the type of vaccination on SARS-CoV-2 infection. Overall, the positive rates were 52.3% and 80.0% for IGRA and 84.6% and 100% for the nAb test before and after booster vaccination, respectively. However, the positive rates were 52.8% for IGRA and 100% for nAb 3 months after booster vaccination. The in vitro test results and the type of vaccination were not associated with SARS-CoV-2 infection. The antibody response caused by the SARS-CoV-2 vaccination lasted more than 6 months, although the response of the T-cells disappeared rapidly after 3 months. However, these in vitro results and the type of vaccination cannot be used for predicting the risk of SARS-CoV-2 infection.

show abstract

“…From the remaining 12 studies, 10 studies met the inclusion criteria [28,17,[29][30][31][32][33][34][35][36]. Regarding the two remaining studies, one article [37] was a letter to the Editor regarding the included study by Krüttgen et al, 2021 [31] and the other article [38] was an authors' reply to this letter and provided additional information regarding the QFN-SARS-CoV-2 Positivity Rate for the aforementioned study and therefore was included in the meta-analysis. Finally, data regarding the use of QFN-SARS-CoV-2 assay from 11 studies were included in the present systematic review and meta-analysis [28,17,[29][30][31][32][33][34][35]38].…”

Section: Literature Searchmentioning

confidence: 99%

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: A Systematic Review and Meta-Analysis

Dourdouna,

Kourlaba,

Michos

2024

Preprint

View full text Add to dashboard Cite

A systematic review and meta-analysis was performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON-SARS-CoV-2 Interferon-γ Release Assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS and medRxiv databases, to identify studies reporting the QuantiFERON-SARS-CoV-2 [Starter (two Antigen tubes) or Starter+Extended Pack (three Antigen tubes), cut-off³0.15IU/mL] Positivity Rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Program Tool. A meta-analysis was conducted using a Random-Effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-75 vaccinated immunocompetent participants) were identified. For COVID-19-naive participants, £3 months after the second dose, the pooled PR (Random-Effects model) was 81 [95% Confidence Interval (95%CI):71-92]%. Comparing the Starter vs. the Starter+Extended Pack, a significant difference in PRs was detected (79.3% vs. 92.2%, p-value=0.039). At 3-6 and >6 months after the second dose and at ³3 months after the third dose, the pooled PRs were 59(95%CI:45-72)%, 79(95%CI:66-92)% and 66(95%CI:50-82)%, respectively. For convalescent participants, ³6 months after the third dose, the pooled PR was 81(95%CI:67-92)%. In conclusion, following the second or third COVID-19 mRNA vaccine, QuantiFERON-SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees. This detection was higher when the Starter+Extended Pack was used. Possible explanations for the assay’s negative results in a subset of the participants could be: waning immunity, reduced sensitivity compared to other T-cell assays or lack of T-cell response induction in some vaccinees. (PROSPERO Registration Number:CRD42023431315)

show abstract

Accuracy of interferon gamma release assays for the COVID-19 immunity assessment

Cited by 5 publications

References 9 publications

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

Exploring the vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 in healthcare workers

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About